Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atara Biotherapeutics, Inc. - Common Stock (NQ: ATRA )

12.41 +0.10 (+0.85%)
Streaming Delayed Price Updated: 10:28 AM EST, Jan 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atara Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Changes to Its Board of Directors
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
NASDAQ:ATRA Shareholder Notice: Investigation over Possible Securities Laws Violations by Atara Biotherapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 08/18/2022 -- Atara Biotherapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update
From Atara Biotherapeutics, Inc.
Via Business Wire
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
ATARA ALERT: Bragar Eagel & Squire, P.C. is Investigating Atara Biotherapeutics, Inc. on Behalf of Atara Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Atara Biotherapeutics, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Patients with Progressive MS
From Atara Biotherapeutics, Inc.
Via Business Wire
Atara Biotherapeutics to Announce Completion of ATA188 Phase 2 EMBOLD Study Interim Analysis on Tuesday, July 12, 2022
From Atara Biotherapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.